Susquehanna International Group, LLP Neu Base Therapeutics, Inc. Call Options Transaction History

Susquehanna International Group, LLP

  • $527 Billion
  • Q2 2024

Call Options

2 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q3 2021

Nov 15, 2021
SELL
$3.27 - $4.76 $159,576 - $232,288
-48,800 Reduced 81.61%
11,000 $40,000
Q2 2021

Aug 11, 2021
BUY
$4.63 - $7.34 $276,874 - $438,932
59,800 New
59,800 $286,000

About NeuBase Therapeutics, Inc.

NBSE Quotes by TradingView
  • Ticker NBSE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 32,258,700
  • Description
  • NeuBase Therapeutics, Inc., a pre-clinical-stage biopharmaceutical company, focuses on the development of therapies to treat rare genetic diseases and cancers caused by mutant genes. The company's proprietary modular peptide-nucleic acid antisense oligo (PATrOL) platform focuses on addressing Huntington's disease (HD) and myotonic dystrophy, as ...
More about NBSE
Track This Portfolio

Track Susquehanna International Group, LLP Portfolio

Follow Susquehanna International Group, LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Susquehanna International Group, LLP with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email